Fulcrum Therapeutics, Inc.
NASDAQ:FULCBiotechnology
+$0.06 today
- Market cap
- $284.14M
- Beta
- 2.92
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.00
Volume 0.63M
Average 1.78M
FULC Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Fulcrum Therapeutics, Inc.NASDAQ: FULC
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses growth accelerates
Q1 FY2026 other income / expenses of $3.3M rose 19.9% year over year, ahead of the -12.7% change in trailing-twelve-month other income / expenses. Sequentially, it rose 39.7% from the prior quarter. Over 3 fiscal years it compounded at +54.3% a year.
Context
- Other income / expenses increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +19.9% holds above the trailing-twelve-month pace of -12.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 9.89M USD
- Year-over-year change
- -18.8%
- 4-year CAGR
- +162.9%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.89M | -18.8% |
| FY2024 | 2024-12-31 | 12.17M | -8.7% |
| FY2023 | 2023-12-31 | 13.33M | +395.5% |
| FY2022 | 2022-12-31 | 2.69M | +1199.5% |
| FY2021 | 2021-12-31 | 207K | — |
Other Income / Expenses vs competitors
How FULC compares with its peers on the latest reported figures
- FULC's LTM Mar 2026 other income / expenses of $10.44M is the 4th highest of the 10 companies compared; the peer median is $745K.
- Its year-over-year change of -12.7% is the 5th highest of 10, against a peer median of -37.5%.
- Over three fiscal years its annual growth of +54.3% compares with a peer median of +75.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $191.32M | +1815.8% | — | 1933.9% | |
| LTM Mar 2026 | $24.78M | -37.5% | +128.9% | 39.0% | |
| LTM Mar 2026 | $12.12M | +36.6% | +113.1% | — | |
| LTM Mar 2026 | $10.44M | -12.7% | +54.3% | — | |
| LTM Mar 2026 | $7M | +6.0% | +37.7% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $745K | -95.5% | -4.3% | — |
| LTM Mar 2026 | -$1.86M | -1250.0% | — | 2.7% | |
| LTM Mar 2026 | -$5.42M | -1137.2% | — | 121.4% | |
| LTM Mar 2026 | -$17.66M | +27.0% | — | 22.3% | |
| LTM Mar 2026 | -$31.59M | -712.7% | — | 213.7% | |
| Peer median (excluding FULC) | $745K | -37.5% | +75.4% | 80.2% | |
Competitors are the stored peer set for FULC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 19.16M | 6.34M | 2.81M | 80M | 0 |
| Cost of Revenue | 69.7M | 76.78M | 71.8M | 63.39M | 1.39M |
| Gross Profit | (50.54M) | (70.44M) | (69M) | 16.61M | (1.39M) |
| Gross Margin | -263.7% | -1110.7% | -2459.8% | 20.8% | — |
| Research & Development | 69.7M | 76.78M | 71.8M | 63.39M | 56.1M |
| Selling, General & Admin | 30.52M | 41.69M | 41.67M | 36.45M | 28.67M |
| Operating Expenses | 30.52M | 42.12M | 41.67M | 38.51M | 83.38M |
| Depreciation & Amortization | 2.52M | 2.41M | 2.17M | 1.59M | 1.39M |
| EBITDA | (78.33M) | (109.72M) | (95.16M) | (18.24M) | (73.49M) |
| EBITDA Margin | -408.8% | -1730.1% | -3392.6% | -22.8% | — |
| Operating Income | (81.05M) | (112.56M) | (110.66M) | (21.9M) | (84.77M) |
| Operating Margin | -423.0% | -1774.9% | -3945.2% | -27.4% | — |
| Interest Income | 207K | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 207K | 2.69M | 13.33M | 12.17M | 9.89M |
| Income Before Tax | (80.85M) | (109.87M) | (97.34M) | (9.73M) | (74.88M) |
| Pre-Tax Margin | -421.9% | -1732.4% | -3470.1% | -12.2% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (80.85M) | (109.87M) | (97.34M) | (9.73M) | (74.88M) |
| Net Margin | -421.9% | -1732.4% | -3470.1% | -12.2% | — |
| EPS (Basic) | (2.22) | (2.35) | (1.59) | (0.16) | (1.18) |
| EPS (Diluted) | (2.22) | (2.35) | (1.59) | (0.16) | (1.18) |
| Weighted Avg Shares | 35.36M | 44.99M | 61.31M | 61.98M | 63.36M |
| Weighted Avg Shares (Diluted) | 35.36M | 44.99M | 61.31M | 61.98M | 63.36M |
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
Intrinsic Alpha fair value
Locked
Current Price
$3.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.